Visceral leishmaniasis (VL) is a group of diseases caused by a parasitic protozoa. Humans are infected via the bite of a type of sandflies, which breed in forest areas, caves, or the burrows of small rodents. VL affects the poorest communities with limited access to diagnosis and treatment. Three most affected countries in the South-East Asia Region are Bangladesh, India and Nepal, while Bhutan has reported sporadic cases. This booklet answers some common questions, and is for the general public as well as health providers.

More information on visceral leishmaniasis and other vector-borne disease is available from the Communicable Diseases Department web site:

http://www.searo.who.int/entity/world_health_day_2014
Frequently Asked Questions on Visceral Leishmaniasis (Kala-azar)
FAQs

Q 1: What is visceral leishmaniasis (VL)?

Q 2: Where is visceral leishmaniasis prevalent?

Q 3: Why is this disease important?

Q 4: Is visceral leishmaniasis a new disease?

Q 5: How does a person get visceral leishmaniasis?

Q 6: What are the signs and symptoms of visceral leishmaniasis?

Q 7: Does infection or getting bitten by the sandflies always lead to illness?

Q 8: How long after being infected does the disease develop?

Q 9: What are the known or presumed reservoirs (the living creatures that host a parasite)?

Q 10: What are the complications of visceral leishmaniasis? Can patients die?

Q 11: Where do the sandflies that transmit the disease live?

Q 12: What are important features of sandfly bites?

Q 13: Do these flies only bite humans?

Q 14: Can the diagnosis of visceral leishmaniasis be confirmed?

Q 15: What is the treatment of visceral leishmaniasis? Is it curable?

Q 16: How was this challenge of cost resolved?

Q 17: How long does the treatment take?

Q 18: Is the treatment safe? What are the possible side-effects?
Q 19: Is there any resistance to this treatment for visceral leishmaniasis? 9
Q 20: Is combining different drugs a better option? 9
Q 21: Given all these complexities regarding visceral leishmaniasis treatment, what is the status in the Indian subcontinent? 10
Q 22: Is there any vaccine for visceral leishmaniasis? 10
Q 23: What are the control strategies for visceral leishmaniasis? 10
Q 24: Can we kill sandflies with insecticide? What are the methods for vector control that are used for visceral leishmaniasis? 10
Q 25: What about using insecticide-treated nets? 11
Q 26: How critical is finding and treating infected patients? 11
Q 27: Given the complexities surrounding visceral leishmaniasis, what can we do to control it? 11
Q 28: How can it be eliminated in the Indian subcontinent? 11
Q 29: What can cause an increase in cases of visceral leishmaniasis? 12
Q 30: I plan to travel to an area where visceral leishmaniasis is found. What can I do to prevent infection? 12
Q 1: What is visceral leishmaniasis (VL)?

Visceral leishmaniasis (VL), also known as kala-azar, is a life-threatening disease caused by the *Leishmania donovani* parasite.

The signs and symptoms of infection with this parasite include anaemia (deficiency in the number or quality of red blood cells), fever, enlarged liver, enlarged spleen and significant weight loss. This disease is often fatal if left untreated. The disease is spread through female sandflies.

Leishmaniasis can occur in three different forms. Visceral leishmaniasis is the most serious form of the disease and causes death in the majority of its victims if left for untreated long time.

Q 2: Where is visceral leishmaniasis prevalent?

Visceral leishmaniasis occurs in more than 70 countries of the world, with a total of 200 million people at risk. However, more than 90% of visceral leishmaniasis cases occur in just seven countries: Bangladesh, India, Nepal, South Sudan, Sudan, Ethiopia and Brazil.

Within the South-East Asia Region, Bangladesh, India and Nepal harbour an estimated 67% of the global visceral leishmaniasis disease burden. In India, most cases occur in the state of Bihar, but other states such as Jharkhand, Uttar Pradesh and West Bengal also report cases. Recently, visceral leishmaniasis has also been reported from Bhutan and Thailand. The visceral leishmaniasis cases are usually concentrated in clear geographical areas – in certain districts or villages. However, population movement means that these boundaries are not always clearly defined.
Q 3: Why is this disease important?

An estimated 200,000 to 400,000 new cases of visceral leishmaniasis occur every year. The annual death toll from the disease is estimated at around 20,000 to 40,000, which is surpassed only by malaria among the parasitic diseases. Visceral leishmaniasis affects the most vulnerable – poor communities in remote, rural areas – and the disease is seen in clusters within households.

It is endemic mostly in countries that are least developed, or in the poorest regions of middle-income nations. Visceral leishmaniasis is diverse and complex, and known to prolong the cycle of poverty as people cannot work and cannot afford treatment.

Q 4: Is visceral leishmaniasis a new disease?

No, the parasite was identified at the beginning of the twentieth century.

Visceral leishmaniasis almost completely disappeared from the Indian subcontinent following the large-scale antimalarial DDT spraying campaign in the 1950s. But the disease quickly re-emerged when these campaigns were terminated and the sandfly population increased again.

Q 5: How does a person get visceral leishmaniasis?

Humans are infected via the bite of sandflies which carry the *Leishmania* parasite inside them. Only female flies can transmit the disease. A single bite from an infected sandfly can inject enough parasites into the bloodstream to infect a human.

Q 6: What are the signs and symptoms of visceral leishmaniasis?

Patients of visceral leishmaniasis suffer from fever, which can increase gradually or suddenly. The fever is persistent and irregular, often with two daily peaks,
and alternating periods of no fever or low-grade fever. Other symptoms include fatigue, weakness, loss of appetite, significant weight loss, and enlarged lymph nodes/glands, enlarge liver and spleen. As the disease advances, the spleen size increases, which may cause abdominal distension and pain.

Post-kala-azar dermal lesion (hyper-pigmentation of skin) may occur after apparent cure of the systemic disease, although this is now very uncommon.

The clinical features of visceral leishmaniasis are not specific and can be easily mistaken for any other common illness that comes with fever.

**Q 7: Does infection or getting bitten by the sandflies always lead to illness?**

No. Infection with *Leishmania* does not always lead to clinical illness, and there are infected people without any symptoms at all. For each sick person, there can be between 3 and 8 people who do not appear ill. Evidence indicates that asymptomatic and subclinical infections are common and apparently induce lasting immunity. The risk factors for developing illness include malnutrition, or if the person has any other disease that reduces immunity, such as HIV/AIDS.

**Q 8: How long after being infected does the disease develop?**

The period between sandfly bite and appearance of symptoms is usually 2 and 6 months, but symptoms can appear as early as 10 days after the bite, or sometimes take years.

**Q 9: What are the known or presumed reservoirs (the living creatures that host a parasite)?**

Reservoirs of the disease include humans, wild oxen and jackals and domestic dogs.

However, humans are the only known reservoir in Bangladesh, India and Nepal.
Q 10: **What are the complications of visceral leishmaniasis? Can patients die?**

Visceral leishmaniasis can eventually lead to death unless treated. Visceral leishmaniasis symptoms often persist for several weeks to months, and weaken the patient so other infections such as pneumonia, diarrhoea or tuberculosis can occur and mask the original symptoms. Patients can die either due to these coinfections, massive bleeding or severe anaemia.

After treatment, 5–10% of patients can also develop post-kala-azar dermal leishmaniasis (PKDL), a skin lesion. It usually appears between 1 and 3 years after the patient was initially cured.

Q 11: **Where do the sandflies that transmit the disease live?**

The sandflies that transmit the disease normally breed in forest areas, caves, cracks in the mud walls, or in the burrows of small rodents. That is why in some villages, where houses are in close proximity to cattle or cattle-sheds, there is a high probability of having sandflies around.

Q 12: **What are important features of sandfly bites?**

People might not realize that sandflies are present because:

- they do not make any noise
- they are small – only about one third the size of mosquitoes, or even smaller
- their bites are painless and might not be noticed.

Sandflies usually are most active during twilight, evening, and from dusk to dawn. But although they are less active during the day, they may bite if they are disturbed (for example, if a person brushes up against the trunk of a tree or other site where they are resting).
Q 13: Do these flies only bite humans?
Not always. In areas with different kinds of *Leishmania* such as *L. infantum*, dogs are the main reservoir. The disease is then known as zoonotic visceral leishmaniasis as it involves animals, and can be found in areas such as China, the Mediterranean basin, the Middle East and South America. In East Africa and South-East Asia, visceral leishmania are harboured only in humans. This is called anthroponotic visceral leishmaniasis, and the disease is eradicable in these areas.

Q 14: Can the diagnosis of visceral leishmaniasis be confirmed?
Yes. There are laboratory tests that can confirm visceral leishmaniasis diagnosis.

- Serological diagnosis – traditionally based on immunofluorescent antibody reaction (IFA) and enzyme-linked immunosorbent assay (ELISA), which are expensive. But cheaper freeze-dried antigen and dipsticks tests are also available.

- The most commonly used tests detect antibodies, which are markers that the body produces after being infected by visceral leishmaniasis. There are different types of antibody test, including:
  - the rapid immunochromatographic method called rK39. The rK39 rapid test has many advantages as it is easy to perform, quick (results in 10–20 minutes) and cheap (around US$ 1 per test). It can be used in remote places and does not require any special equipment or training. They are currently the best diagnostic tool available.
  - the direct agglutination test (DAT).
● The polymerase chain reaction (PCR) technique is the most sensitive test, but it remains expensive.

● The “gold standard” proof of visceral leishmaniasis is seeing the parasite through microscopic examination. But the procedures to get the samples require considerable technical expertise and are potentially dangerous, and so cannot be performed everywhere.

Q 15: What is the treatment of visceral leishmaniasis? Is it curable?

Yes, visceral leishmaniasis is curable with proper treatment. However, initially there were few medical options to treat visceral leishmaniasis and even those were not always easily available. Visceral leishmaniasis is difficult to treat mainly because most of the drugs have to be given through injection, requiring hospitalization and close monitoring.

The mainstay of treatment for more than 70 years was sodium stibogluconate (SSG) and meglumine antimoniate, which are pentavalent antimonial drugs containing an element similar to arsenic.

Other drugs include conventional amphotericin B (an anti-fungal drug which has many side-effects), liposomal amphotericin B (shortened to LAmB, which has relatively fewer side-effects), and paromomycin.

Miltefosine, which was initially developed as an anti-cancer drug, is the first effective oral drug for visceral leishmaniasis.

LAmB is now the treatment of choice. The total dose required is different among regions, with a lower dose sufficient in the Indian subcontinent.
compared to Africa or Latin America. In developing countries, the use of this drug was limited because it is expensive.

Q 16: How was this challenge of cost resolved?

An agreement was reached in 2007 between WHO and Gilead, the manufacturer of LAmB, to reduce the price. It initially cost US$ 2800 per treatment, but now the price is down to US$ 200. Old drugs such as SSG are still inexpensive.

Q 17: How long does the treatment take?

This depends on which drug is used:

- With SSG only, the patient needs a daily injection for 28 days.
- Paromomycin alone needs 21 days.
- Miltefosine alone is typically given for 28 days.
- A recent breakthrough is a single dose of injectable liposomal amphotericin B (LAmB), which significantly improves compliance to treatment.

Multiple studies have confirmed the efficacy of LAmB against visceral leishmaniasis parasites in the Indian subcontinent. Therefore, single-dose LAmB has been recommended as the first-line visceral leishmaniasis treatment.

Q 18: Is the treatment safe? What are the possible side-effects?

Side-effects vary.

- Antimonials are toxic drugs with frequent, sometimes life threatening adverse effects such as heart problems and acute pancreatitis.
● Amphotericin B could cause damage to the kidneys or trigger severe allergic reactions. The liposomal form has far fewer side-effects.

● Miltefosine can cause birth defects and cannot be used by pregnant women or women who could become pregnant within two months of treatment. It can sometimes cause gastrointestinal side-effects. It also has a long half-life, meaning it stays in the body for a very long time, which could potentially make the parasite resistant to it.

Q 19: Is there any resistance to this treatment for visceral leishmaniasis?

Yes. Antimonials (SSG) treatment has been widely misused in the past (by splitting daily doses, using improper dosages and substandard batches of drugs). This has led to the emergence of widespread resistance, sometimes as high as 60–80%. This required a change in drug policy.

In unregulated private health care systems, patients often receive inappropriate treatment courses and this in turn can contribute to the emergence of resistance. This is of particular concern for Miltefosine, as this drug has a long half-life.

Q 20: Is combining different drugs a better option?

Every drug seems to have its drawback. Combination therapy has been advocated as a way to increase treatment efficacy and tolerance, reduce treatment length and cost, and limit the emergence of drug resistance. However, the choice of drugs and the most optimal dosage are still being debated. Several clinical studies are being undertaken to provide more data on the safety and efficacy of different combination therapies.
Regional factors also play a role, with the eastern Africa region still using antimonials as first-line treatment, while in the Indian subcontinent there are more treatment options. There is scientific evidence that combination therapies are a cost-effective alternative.

**Q 21:** Given all these complexities regarding visceral leishmaniasis treatment, what is the status in the Indian subcontinent?

Several breakthroughs in the treatment of visceral leishmaniasis have been reported over the past decade. In 2010, WHO recommended a treatment regimen for anthropontic visceral leishmaniasis caused by *L. donovani* in Bangladesh, Bhutan, India and Nepal.

**Q 22:** Is there any vaccine for visceral leishmaniasis?

No, not yet. Anti-leishmanial vaccines are still under development.

**Q 23:** What are the control strategies for visceral leishmaniasis?

The current control strategies rely on reservoir and vector control – and, of course, early diagnosis and treatment of cases. When the burden of disease is high, active case finding can also be carried out.

**Q 24:** Can we kill sandflies with insecticide? What are the methods for vector control that are used for visceral leishmaniasis?

Sandflies are susceptible to the same insecticides as the malaria vector, and residual insecticide spraying of houses and animal shelters has been shown to be successful in India. Another method is environmental control, such as plastering cracks in the house wall and moving away from animal shelters.
Q 25: What about using insecticide-treated nets?

The use of insecticide-impregnated/treated bednets could also prevent visceral leishmaniasis as well as other vector-borne diseases such as malaria or Japanese encephalitis. However, there is limited evidence that bednets provide protection against visceral leishmaniasis in particular, as effectiveness of the bednets depends on the sleeping habits of the population and the biting habits of the local vectors.

Q 26: How critical is finding and treating infected patients?

Visceral leishmaniasis can kill if it is left untreated. People who are not treated can also act as a reservoir for parasites and therefore contribute to the spread of the disease. Similarly, post kala-azar dermal leishmaniasis patients are likely to be highly infectious because large numbers of parasites are present in the skin lesions. Therefore, it is critical to identify and treat infected patients.

Q 27: Given the complexities surrounding visceral leishmaniasis, what can we do to control it?

Early diagnosis and treatment of visceral leishmaniasis remain very important. Countries that have visceral leishmaniasis pockets must ensure that diagnostic tests and medicines are available in the health facilities. Vector control is another cornerstone for controlling the disease. With the recent attention on neglected diseases, some national programmes are being boosted to help control the disease.

Q 28: How can it be eliminated in the Indian subcontinent?

Despite the difficulties in controlling visceral leishmaniasis globally, there are several factors specific to the Indian subcontinent that make elimination feasible.
● Humans are the only reservoir and *Phlebotomus argentipes* sandflies the only known vector for the parasite, so if we can interrupt transmission in humans, it can be eliminated.

● New and more effective diagnostic tests (the rK39 immunochromatographic) and drugs (such as miltefosine) are available and can be used in the field.

● Most importantly, there is a strong political commitment and intercountry collaboration to check the disease.

The visceral leishmaniasis elimination initiative was launched in 2005 by the signing of a Memorandum of Understanding among Bangladesh, India and Nepal. The target for elimination is set for 2015.

**Q 29: What can cause an increase in cases of visceral leishmaniasis?**

Environmental factors such as deforestation, urbanization and migration of non-immune people to endemic areas have led to an increase in the incidence of visceral leishmaniasis. In countries with high HIV prevalence (such as Ethiopia), the coinfection between HIV and visceral leishmaniasis is a potential catastrophe, as patients are more difficult to diagnose and treat, and are more likely to relapse.

**Q 30: I plan to travel to an area where visceral leishmaniasis is found. What can I do to prevent infection?**

No vaccines or drugs to prevent infection are available at the moment. The best way for travellers to prevent infection is to protect themselves from sandfly bites.
Visceral leishmaniasis (VL) is a group of diseases caused by a parasitic protozoa. Humans are infected via the bite of a type of sandflies, which breed in forest areas, caves, or the burrows of small rodents. VL affects the poorest communities with limited access to diagnosis and treatment. Three most affected countries in the South-East Asia Region are Bangladesh, India and Nepal, while Bhutan has reported sporadic cases. This booklet answers some common questions, and is for the general public as well as health providers.

More information on visceral leishmaniasis and other vector-borne disease is available from the Communicable Diseases Department web site:
http://www.searo.who.int/entity/world_health_day_2014